Nature Communications (Mar 2022)
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
- Lei Peng,
- Yingxia Hu,
- Madeleine C. Mankowski,
- Ping Ren,
- Rita E. Chen,
- Jin Wei,
- Min Zhao,
- Tongqing Li,
- Therese Tripler,
- Lupeng Ye,
- Ryan D. Chow,
- Zhenhao Fang,
- Chunxiang Wu,
- Matthew B. Dong,
- Matthew Cook,
- Guilin Wang,
- Paul Clark,
- Bryce Nelson,
- Daryl Klein,
- Richard Sutton,
- Michael S. Diamond,
- Craig B. Wilen,
- Yong Xiong,
- Sidi Chen
Affiliations
- Lei Peng
- Department of Genetics, Yale University School of Medicine
- Yingxia Hu
- Department of Molecular Biophysics and Biochemistry, Yale University
- Madeleine C. Mankowski
- Department of Laboratory Medicine, Yale University
- Ping Ren
- Department of Genetics, Yale University School of Medicine
- Rita E. Chen
- Departments of Medicine and Pathology & Immunology, Washington University School of Medicine in St. Louis
- Jin Wei
- Department of Laboratory Medicine, Yale University
- Min Zhao
- Section of Infectious Diseases, Department of Internal Medicine, Yale University
- Tongqing Li
- Department of Pharmacology, Yale University School of Medicine
- Therese Tripler
- Department of Molecular Biophysics and Biochemistry, Yale University
- Lupeng Ye
- Department of Genetics, Yale University School of Medicine
- Ryan D. Chow
- Department of Genetics, Yale University School of Medicine
- Zhenhao Fang
- Department of Genetics, Yale University School of Medicine
- Chunxiang Wu
- Department of Molecular Biophysics and Biochemistry, Yale University
- Matthew B. Dong
- Department of Genetics, Yale University School of Medicine
- Matthew Cook
- Department of Molecular Biophysics and Biochemistry, Yale University
- Guilin Wang
- Yale Center for Genome Analysis, Yale University
- Paul Clark
- Department of Genetics, Yale University School of Medicine
- Bryce Nelson
- Department of Pharmacology, Yale University School of Medicine
- Daryl Klein
- Department of Pharmacology, Yale University School of Medicine
- Richard Sutton
- Section of Infectious Diseases, Department of Internal Medicine, Yale University
- Michael S. Diamond
- Departments of Medicine and Pathology & Immunology, Washington University School of Medicine in St. Louis
- Craig B. Wilen
- Department of Laboratory Medicine, Yale University
- Yong Xiong
- Department of Molecular Biophysics and Biochemistry, Yale University
- Sidi Chen
- Department of Genetics, Yale University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-29288-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Despite effective vaccines against SARS-CoV-2, therapeutic options such as anti-virals and neutralizing antibodies are critical in treating disease, especially given the breakthrough infections of emerging VOCs. Here, Peng et al. generate two potent monoclonal antibodies and a bispecific antibody with two antigenrecognition variable regions targeting SARS-CoV-2 spike, provide CryoEM structures and show in vitro and in vivo efficacy of a humanized antibody against wildtype virus and delta variant.
